Radiation Safety Research Center, Nuclear Technology Research Laboratory, Central Research Institute of Electric Power Industry (CRIEPI), 2-11-1 Iwado-kita, Komae, Tokyo, 201-8511, Japan.
Clinical Department, Southern Urals Biophysics Institute, Ozyorskoe Shosse 19, Ozyorsk Chelyabinsk Region, 456780, Russia.
Mutat Res Rev Mutat Res. 2019 Jan-Mar;779:36-44. doi: 10.1016/j.mrrev.2019.01.001. Epub 2019 Jan 8.
Glaucoma is a group of optic neuropathies causing optic nerve damage and visual field defects, and is one of the leading causes of blindness. Nearly a century has passed since the first report of glaucoma manifested following ionizing radiation therapy of cancers. Nevertheless, associations between glaucoma and radiation exposures, a dose response relationship, and the mechanistic underpinnings remain incompletely understood. Here we review the current knowledge on manifestations and mechanisms of radiogenic glaucoma. There is some evidence that neovascular glaucoma is manifest relatively quickly, within a few years after high-dose and high dose-rate radiotherapeutic exposure, but little evidence of excess risks of glaucoma after exposure to much lower doses or dose rates. As such, glaucoma appears to have some of the characteristics of a tissue reaction effect, with a threshold of at least 5 Gy but possibly much higher.
青光眼是一组视神经病变,可导致视神经损伤和视野缺陷,是失明的主要原因之一。自首次报道癌症放射治疗后出现青光眼以来,已经过去了近一个世纪。然而,青光眼与辐射暴露之间的关联、剂量反应关系和潜在机制仍不完全清楚。在这里,我们回顾了放射性青光眼的表现和机制的现有知识。有一些证据表明,新生血管性青光眼在高剂量和高剂量率放射治疗暴露后的几年内相对较快地出现,但在暴露于低得多的剂量或剂量率后,青光眼的风险增加几乎没有证据。因此,青光眼似乎具有组织反应效应的一些特征,其阈值至少为 5Gy,但也可能更高。